Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Coagulation01:09

Coagulation

The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
Coagulation01:06

Coagulation

Colloidal solids are solid particles suspended in solution. They are usually negatively charged, attracting a compact primary layer of positively charged ions, which attract more counterions to form an electrical double layer. Electrostatic repulsion between the charged double layers prevents the particles from colliding, stabilizing the colloids. These solids are often undesirable because they can contain toxins that are difficult to remove. Coagulation is a technique that helps aggregate and...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
Cancer02:18

Cancer

Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Arterial and venous thromboembolism in hospitalized patients with COVID-19: a national multicenter cohort study.

Blood vessels, thrombosis & hemostasis·2026
Same author

Management of cancer-associated thrombosis in patients with gastrointestinal cancers: lights and shadows.

Cancer treatment reviews·2026
Same author

Addition of malignancy into the CHADS2/CHA2DS2VASc score: better prediction of stroke risk in individuals with cancer and atrial fibrillation.

Cardio-oncology (London, England)·2026
Same author

Guidelines Can Be Lifesaving: The Vermont Model of Thromboprophylaxis Implementation.

JCO oncology practice·2026
Same author

Antithrombotic therapy at the end-of-life-continue or stop?

Research and practice in thrombosis and haemostasis·2026
Same author

Phase 2 trial of exercise and low-dose ibuprofen for cancer-related cognitive impairment in patients receiving chemotherapy.

Cancer·2026

Related Experiment Video

Updated: May 24, 2026

Venous Thrombosis Assay in a Mouse Model of Cancer
04:40

Venous Thrombosis Assay in a Mouse Model of Cancer

Published on: January 5, 2024

Cancer and coagulation.

Alok A Khorana1

  • 1James P Wilmot Cancer Center and the Department of Medicine, University of Rochester, Rochester, New York, USA. alok_khorana@urmc.rochester.edu

American Journal of Hematology
|March 6, 2012
PubMed
Summary

Cancer patients frequently experience thromboembolism, impacting mortality and healthcare costs. Prophylaxis with heparins is safe and effective in high-risk settings, with ongoing research into novel anticoagulants.

Area of Science:

  • Oncology
  • Hematology
  • Vascular Medicine

Background:

  • Thromboembolism is a common and serious complication in cancer patients.
  • It significantly increases mortality, morbidity, and healthcare resource utilization.
  • Understanding risk factors and biomarkers is crucial for management.

Purpose of the Study:

  • To review current understanding and management of cancer-associated thrombosis.
  • To highlight the role of risk assessment models and thromboprophylaxis.
  • To discuss emerging data on novel anticoagulants.

Main Methods:

  • Review of recent studies on cancer-associated thrombosis.
  • Analysis of clinical risk factors and biomarkers.
  • Evaluation of thromboprophylaxis strategies including heparins.

More Related Videos

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
04:37

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Published on: May 23, 2025

Co-Culture In Vitro Systems to Reproduce the Cancer-Immunity Cycle
12:19

Co-Culture In Vitro Systems to Reproduce the Cancer-Immunity Cycle

Published on: June 7, 2024

Related Experiment Videos

Last Updated: May 24, 2026

Venous Thrombosis Assay in a Mouse Model of Cancer
04:40

Venous Thrombosis Assay in a Mouse Model of Cancer

Published on: January 5, 2024

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
04:37

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation

Published on: May 23, 2025

Co-Culture In Vitro Systems to Reproduce the Cancer-Immunity Cycle
12:19

Co-Culture In Vitro Systems to Reproduce the Cancer-Immunity Cycle

Published on: June 7, 2024

  • Consideration of emerging data on novel anticoagulants.

    • Main Results:

    • Validated risk assessment models incorporating clinical factors and biomarkers improve prediction.
    • Thromboprophylaxis with unfractionated heparin or low-molecular-weight heparins (LMWHs) is safe and effective in hospitalized and postsurgical patients.
    • Outpatient prophylaxis shows potential benefits.

    Conclusions:

    • Cancer-associated thrombosis requires effective management strategies.
    • Heparins are established for prophylaxis and treatment in specific settings.
    • Further research on novel anticoagulants is needed for comprehensive care.